Ifp Advisors, Inc Fibrogen Inc Transaction History

Ifp Advisors, Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 12, 2022	SELL	$9.93 - $15.39 $139 - $215	-14 Reduced 41.18%	20 $1,000
Q3 2021 Oct 06, 2021	BUY	$10.18 - $26.64 $346 - $905	34 New	34 $1,000
Q2 2021 Jul 13, 2021	SELL	$18.57 - $35.68 $24,790 - $47,632	-1,335 Closed	0 $0
Q1 2021 Apr 30, 2021	BUY	$31.0 - $55.72 $5,053 - $9,082	163 Added 13.91%	1,335 $45,000
Q4 2020 Jan 25, 2021	SELL	$37.09 - $48.97 $21,660 - $28,598	-584 Reduced 33.26%	1,172 $40,000
Q3 2020 Oct 29, 2020	BUY	$40.47 - $45.5 $11,048 - $12,421	273 Added 18.41%	1,756 $72,000
Q2 2020 Aug 05, 2020	BUY	$32.57 - $42.83 $618 - $813	19 Added 1.3%	1,483 $60,000
Q1 2020 May 12, 2020	BUY	$23.3 - $45.96 $722 - $1,424	31 Added 2.16%	1,464 $50,000
Q4 2019 Jan 17, 2020	SELL	$34.58 - $48.06 $3,043 - $4,229	-88 Reduced 5.79%	1,433 $66,000
Q3 2019 Nov 07, 2019	BUY	$36.98 - $48.45 $56,246 - $73,692	1,521 New	1,521 $60,000
Q1 2019 May 15, 2019	SELL	$42.83 - $59.91 $256 - $359	-6 Closed	0 $0
Q3 2018 Oct 25, 2018	SELL	$56.3 - $67.25 $1,069 - $1,277	-19 Reduced 76.0%	6 $0
Q2 2018 Aug 07, 2018	BUY	$44.9 - $64.95 $853 - $1,234	19 Added 316.67%	25 $0
Q3 2017 Oct 30, 2017	BUY	$33.4 - $53.9 $200 - $323	6	6 $0

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.